Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "CrisprBits"

3 News Found

CrisprBits collaborates with Molbio Diagnostics to launch CRISPR-based Point-of-Care tests
Clinical Trials | August 16, 2023

CrisprBits collaborates with Molbio Diagnostics to launch CRISPR-based Point-of-Care tests

CrisprBits has developed a platform to build rapid, precise, and affordable POC tests for a wide range of disease and health conditions

CrisprBits develops CRISPR-based SARS-CoV2 test OmiCrisp
Biotech | January 25, 2023

CrisprBits develops CRISPR-based SARS-CoV2 test OmiCrisp

OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program

C-CAMP launches NBEC 2026 with up to Rs 20 Crore in prizes and investment opportunities
Biopharma | May 04, 2026

C-CAMP launches NBEC 2026 with up to Rs 20 Crore in prizes and investment opportunities

India’s largest life sciences entrepreneurship competition opens applications for startups, innovators and student teams nationwide

Upcoming E-conference
June 19, 2026 The Future of Clinical Research in India: Can India Become a Global Trial Hub?
July 17, 2026 Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma

Latest Stories

Alithea Genomics and Revvity expand global access to scalable transcriptomics platforms

Lumos Health opens applications for second cohort of HealthTech and MedTech startups

India’s bioeconomy grew 20-fold in last 12 years: Dr Jitendra Singh

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
Akhil Ravi Chief Executive Officer, Aurigene Pharmaceutical Services Limited
Our D2 lamp portfolio caters to entire spectrum of chromatography and spectroscopy customers: Hemang Jhaveri, Partner, Hiten Techno Products Corporation
Our D2 lamp portfolio caters to entire spectrum of chromatography and spectroscopy customers: Hemang Jhaveri, Partner, Hiten Techno Products Corporation
From bench to work flow, we are an integrated solution provider: K.O. Satish, Associate Vice President, Spinco Biotech
From bench to work flow, we are an integrated solution provider: K.O. Satish, Associate Vice President, Spinco Biotech

Packaging